J&J Tops Q3 Expectations, Raises Full-Year Adjusted EPS Guidance
JNJ sits 40% above its 52-week low of $184.66.
Summary
Johnson & Johnson beat Q3 2026 expectations and raised its full-year adjusted EPS guidance to $11.05-$11.15 from $10.96-$11.11. The company also raised the low end of its sales forecast to a midpoint of $101.2B. This follows a volatile guidance path: the company raised guidance after Q2, then cut it in late July due to the Firefly Bio acquisition and Sail Biomedicines collaboration. The new raise suggests Q3 performance offset those headwinds. MedTech sales missed estimates.
Updated with a Dow Jones Newswires report · What changed
Updates
· SEC 8-K — J&J's 8-K attaches the Q3 press release and supplementary sales data; adjusted EPS was $2.59, and full-year adjusted EPS guidance was raised to $11.05-$11.15.
· Dow Jones Newswires — J&J raised FY adjusted EPS guidance to $11.05-$11.15 from $10.96-$11.11 and raised low end of sales forecast to midpoint $101.2B; MedTech sales missed estimates.
At the time of this announcement, JNJ was trading at $259.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $635.6B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.